Page last updated: 2024-12-09

pyrimidine-2-thiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrimidine-2-thiol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyrimidine-2-thiol : Pyrimidine substituted at C-2 by a sulfanyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1550489
CHEMBL ID1688952
CHEBI ID53576
SCHEMBL ID37899
SCHEMBL ID10977267
MeSH IDM0176461

Synonyms (61)

Synonym
nsc193522
1450-85-7
2(1h)-pyrimidinethione
2-mercaptopyrimidine
nsc-193522
2-pyrimidinethione
2-thiopyrimidine
nsc-48073
nsc48073
2-mercaptopyrimidine, 98%
1h-pyrimidine-2-thione
pyrimidine-2-thiol
mpy ,
thiopyrimidine
inchi=1/c4h4n2s/c7-4-5-2-1-3-6-4/h1-3h,(h,5,6,7
CHEBI:53576 ,
2-pyrimidinethiol
M0937
AKOS000119746
CHEMBL1688952
dtxsid6049220 ,
NCGC00260351-01
dtxcid8029076
tox21_202805
cas-1450-85-7
einecs 258-741-2
pyrimidine-1-thiol
53745-18-9
einecs 215-917-3
nsc 193522
nsc 48073
131242-36-9
2-pyrimidinethiol (9ci)
FT-0612773
BBL025630
STL367769
EPITOPE ID:120364
pyrimidinethione
AKOS022187337
SCHEMBL37899
2-mercapto-pyrimidine
pyrimidine-2-thione
mercaptopyrimidine
pyrimidine-2(1h)-thione
SCHEMBL10977267
STR00484
2-pyrimidinethiol #
mfcd00006073
F3329-0411
1,2-dihydropyrimidine-2-thione
J-008052
SY048492
Q27124108
AM10234
CS-0043556
2-thioxopyrimidine
SB57498
E80918
EN300-17793
2-sulfanylpyrimidine
T72Z5M7P5T

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The in vivo toxicological assessment performed on zebrafish embryos revealed that complexes (1) and (2) did not present embryotoxic or toxic effects during embryonic and larval development showing that they are promising new prototypes of safer and more effective drugs for triple negative breast cancer treatment."( In vitro cytotoxicity and in vivo zebrafish toxicity evaluation of Ru(ii)/2-mercaptopyrimidine complexes.
Batista, AA; Deflon, VM; Ellena, J; Ferreira, AG; Goveia, RM; Grisolia, CK; Lima, AP; Mello-Andrade, F; Oliveira, KM; Pereira, LR; Pires, WC; Rezende, MRM; Silva, MM; Silveira-Lacerda, EP; Velozo-Sá, VS, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
corrosion inhibitorA chemical compound that, when added to a liquid or gas, decreases the corrosion rate of a material, typically a metal or an alloy.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
aryl thiolAn aryl thiol is a thiol in which a sulfanyl group, SH, is attached to an aryl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency77.03710.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency45.93090.000714.592883.7951AID1259369; AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency42.60360.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency77.03710.003041.611522,387.1992AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.65940.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency43.88360.000229.305416,493.5996AID743075; AID743077; AID743079
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.174119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency49.05610.057821.109761.2679AID1159526; AID1159528
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency32.97190.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID756681Activation of AMPK in rat L6 cells assessed as increase of [3H]dGlc uptake at 100 uM after 5 hrs in presence of insulin2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID584549Activation of Bacillus anthracis Sterne 34F2 spore germination after 1 hr2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID756690Activation of AMPK in rat L6 cells assessed as increase of [3H]dGlc uptake at 100 uM after 5 hrs relative to control2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID756686Activation of AMPKalpha in rat L6 cells assessed as phosphorylation at Thr172 after 40 mins to 24 hrs by Western blot analysis2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's0 (0.00)18.2507
2000's8 (50.00)29.6817
2010's7 (43.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.95 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]